Cargando…
Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment
OBJECTIVE: Although most HIV-infected individuals achieve undetectable viremia during antiretroviral therapy (ART), a subset have low-level viremia (LLV) of varying duration and magnitude. The impact of LLV on treatment outcomes is unclear. We investigated the association between LLV and virological...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500364/ https://www.ncbi.nlm.nih.gov/pubmed/28683128 http://dx.doi.org/10.1371/journal.pone.0180761 |
_version_ | 1783248618722951168 |
---|---|
author | Elvstam, Olof Medstrand, Patrik Yilmaz, Aylin Isberg, Per-Erik Gisslén, Magnus Björkman, Per |
author_facet | Elvstam, Olof Medstrand, Patrik Yilmaz, Aylin Isberg, Per-Erik Gisslén, Magnus Björkman, Per |
author_sort | Elvstam, Olof |
collection | PubMed |
description | OBJECTIVE: Although most HIV-infected individuals achieve undetectable viremia during antiretroviral therapy (ART), a subset have low-level viremia (LLV) of varying duration and magnitude. The impact of LLV on treatment outcomes is unclear. We investigated the association between LLV and virological failure and/or all-cause mortality among Swedish patients receiving ART. METHODS: HIV-infected patients from two Swedish HIV centers were identified from the nationwide register InfCare HIV. Subjects aged ≥15 years with triple agent ART were included at 12 months after treatment initiation if ≥2 following viral load measurements were available. Patients with 2 consecutive HIV RNA values ≥1000 copies/mL at this time point were excluded. Participants were stratified into four categories depending on viremia profiles: permanently suppressed viremia (<50 copies/mL), LLV 50–199 copies/mL, LLV 200–999 copies/mL and viremia ≥1000 copies/mL. Association between all four viremia categories and all-cause death was calculated using survival analysis with viremia as a time-varying covariate, so that patients could change viremia category during follow-up. Association between the three lower categories and virological failure (≥2 consecutive measurements ≥1000 copies/mL) was calculated in a similar manner. RESULTS: LLV 50–199 copies/mL was recorded in 70/1015 patients (6.9%) and LLV 200–999 copies/mL in 89 (8.8%) during 7812 person-years of follow-up (median 6.5 years). LLV 200–999 copies/mL was associated with virological failure (adjusted hazard ratio 3.14 [95% confidence interval 1.41–7.03, p<0.01]), whereas LLV 50–199 copies/mL was not (1.01 [0.34–4.31, p = 0.99]; median follow-up 4.5 years). LLV 200–999 copies/mL had an adjusted mortality hazard ratio of 2.29 (0.98–5.32, p = 0.05) and LLV 50–199 copies/mL of 2.19 (0.90–5.37, p = 0.09). CONCLUSIONS: In this Swedish cohort followed during ART for a median of 4.5 years, LLV 200–999 copies/mL was independently associated with virological failure. Patients with LLV had higher rates of all-cause mortality, although not statistically significant in multivariate analysis. |
format | Online Article Text |
id | pubmed-5500364 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-55003642017-07-11 Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment Elvstam, Olof Medstrand, Patrik Yilmaz, Aylin Isberg, Per-Erik Gisslén, Magnus Björkman, Per PLoS One Research Article OBJECTIVE: Although most HIV-infected individuals achieve undetectable viremia during antiretroviral therapy (ART), a subset have low-level viremia (LLV) of varying duration and magnitude. The impact of LLV on treatment outcomes is unclear. We investigated the association between LLV and virological failure and/or all-cause mortality among Swedish patients receiving ART. METHODS: HIV-infected patients from two Swedish HIV centers were identified from the nationwide register InfCare HIV. Subjects aged ≥15 years with triple agent ART were included at 12 months after treatment initiation if ≥2 following viral load measurements were available. Patients with 2 consecutive HIV RNA values ≥1000 copies/mL at this time point were excluded. Participants were stratified into four categories depending on viremia profiles: permanently suppressed viremia (<50 copies/mL), LLV 50–199 copies/mL, LLV 200–999 copies/mL and viremia ≥1000 copies/mL. Association between all four viremia categories and all-cause death was calculated using survival analysis with viremia as a time-varying covariate, so that patients could change viremia category during follow-up. Association between the three lower categories and virological failure (≥2 consecutive measurements ≥1000 copies/mL) was calculated in a similar manner. RESULTS: LLV 50–199 copies/mL was recorded in 70/1015 patients (6.9%) and LLV 200–999 copies/mL in 89 (8.8%) during 7812 person-years of follow-up (median 6.5 years). LLV 200–999 copies/mL was associated with virological failure (adjusted hazard ratio 3.14 [95% confidence interval 1.41–7.03, p<0.01]), whereas LLV 50–199 copies/mL was not (1.01 [0.34–4.31, p = 0.99]; median follow-up 4.5 years). LLV 200–999 copies/mL had an adjusted mortality hazard ratio of 2.29 (0.98–5.32, p = 0.05) and LLV 50–199 copies/mL of 2.19 (0.90–5.37, p = 0.09). CONCLUSIONS: In this Swedish cohort followed during ART for a median of 4.5 years, LLV 200–999 copies/mL was independently associated with virological failure. Patients with LLV had higher rates of all-cause mortality, although not statistically significant in multivariate analysis. Public Library of Science 2017-07-06 /pmc/articles/PMC5500364/ /pubmed/28683128 http://dx.doi.org/10.1371/journal.pone.0180761 Text en © 2017 Elvstam et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Elvstam, Olof Medstrand, Patrik Yilmaz, Aylin Isberg, Per-Erik Gisslén, Magnus Björkman, Per Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment |
title | Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment |
title_full | Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment |
title_fullStr | Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment |
title_full_unstemmed | Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment |
title_short | Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment |
title_sort | virological failure and all-cause mortality in hiv-positive adults with low-level viremia during antiretroviral treatment |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5500364/ https://www.ncbi.nlm.nih.gov/pubmed/28683128 http://dx.doi.org/10.1371/journal.pone.0180761 |
work_keys_str_mv | AT elvstamolof virologicalfailureandallcausemortalityinhivpositiveadultswithlowlevelviremiaduringantiretroviraltreatment AT medstrandpatrik virologicalfailureandallcausemortalityinhivpositiveadultswithlowlevelviremiaduringantiretroviraltreatment AT yilmazaylin virologicalfailureandallcausemortalityinhivpositiveadultswithlowlevelviremiaduringantiretroviraltreatment AT isbergpererik virologicalfailureandallcausemortalityinhivpositiveadultswithlowlevelviremiaduringantiretroviraltreatment AT gisslenmagnus virologicalfailureandallcausemortalityinhivpositiveadultswithlowlevelviremiaduringantiretroviraltreatment AT bjorkmanper virologicalfailureandallcausemortalityinhivpositiveadultswithlowlevelviremiaduringantiretroviraltreatment |